Record Results for ResMed

SAN DIEGO — Last week ResMed reported record revenue for
the company’s second quarter and six months, ended Dec. 31. Revenue
for the quarter was $306 million, an 11 percent increase over the
same quarter in 2009, while revenue grew 13 percent to $588 million
for the six months.

“We expect the growth of all of our products to continue to
benefit from the vastly under-penetrated and growing
sleep-disordered breathing market,” Kieran T. Gallahue, president
and CEO, said in a release.

He added that evidence coming to light shows early intervention
in the treatment of SDB may slow or prevent the progression of
co-morbidities such as obesity, hypertension, heart disease or
drug-resistant hypertension. “The increase in awareness of the role
that SDB plays in these costly and debilitating co-morbidities and
in the reduction in workplace safety and productivity should
continue to be a major driver of market expansion,” Gallahue
said.